Floatz logo

Polyiclc

Clinical Stage IV Cutaneous Melanoma AJCC v8

Fred Hutchinson Cancer CenterPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Clinical Stage IV Cutaneous Melanoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Irinotecan
GI Innovation, Inc.
Phase 2BBB
Ipilimumab
Amsterdam UMC, location VUmc
Phase 3BB
Binimetinib
Leiden University Medical Center
Phase 3BB
Epirubicin
Aminex Therapeutics, Inc.
Phase 3BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB

View all 18 →

Same molecule, other indications

Polyiclc is also rated in:

ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
Metastatic Triple-Negative Breast CarcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →